Lung's LTI-01 may dissolve fibrin, spare surgery in complicated pleural effusion
Lung Therapeutics Inc. is developing therapies that prevent or resolve fibrosis to treat Orphan lung diseases. Lead product LTI-01 is a formulation of a fibrinolytic enzyme in preclinical development to prevent and clear loculated pleural effusion without resorting to surgery.
Pleural effusion is a complication of pneumonia or inflammation-related conditions in which fluid builds up in the lungs. When the fluid causes loculation, or scar tissue formation, pockets may form that cannot be drained by a chest tube, causing pain, shortness of breath and increased risk